ITGAV and ovarian cancer: This miR targets Sirtuin 1 (SIRT1) and represses the proliferation and chemoresistance in ovarian cancer [45] and targets the Wiskott–Aldrich syndrome-like protein (WASL), Integrin Alpha V, and other cytoskeletal components.